These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23273681)

  • 1. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Margulis V; Shariat SF; Rapoport Y; Rink M; Sjoberg DD; Tannir NM; Abel EJ; Culp SH; Tamboli P; Wood CG
    Eur Urol; 2013 May; 63(5):947-52. PubMed ID: 23273681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative C-Reactive Protein Values as a Potential Component in Outcome Prediction Models of Metastasized Renal Cell Carcinoma Patients Receiving Cytoreductive Nephrectomy.
    Kalogirou C; Mulfinger P; Sokolakis I; Krebs M; Kübler H; Riedmiller H; Vergho D
    Urol Int; 2017; 99(3):297-307. PubMed ID: 28624829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Marconi L; de Bruijn R; van Werkhoven E; Beisland C; Fife K; Heidenreich A; Kapoor A; Karam J; Kauffmann C; Klatte T; Ljungberg B; Matin S; Sjoberg D; Staehler M; Stewart GD; Tanguay S; Uzzo R; Welsh S; Wood L; Wood C; Bex A
    World J Urol; 2018 Dec; 36(12):1973-1980. PubMed ID: 30069581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models.
    Manley BJ; Tennenbaum DM; Vertosick EA; Hsieh JJ; Sjoberg DD; Assel M; Benfante NE; Strope SA; Kim E; Casuscelli J; Becerra MF; Coleman JA; Hakimi AA; Russo P
    Urol Oncol; 2017 Jan; 35(1):35.e1-35.e5. PubMed ID: 27567689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma.
    Chapin BF; Delacroix SE; Culp SH; Nogueras Gonzalez GM; Tannir NM; Jonasch E; Tamboli P; Wood CG
    Eur Urol; 2011 Nov; 60(5):964-71. PubMed ID: 21621907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
    Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
    J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?
    Culp SH; Tannir NM; Abel EJ; Margulis V; Tamboli P; Matin SF; Wood CG
    Cancer; 2010 Jul; 116(14):3378-88. PubMed ID: 20564061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
    Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules.
    Adibi M; Kenney PA; Thomas AZ; Borregales LD; Nogueras-González GM; Wang X; Devine CE; Karam JA; Wood CG
    Eur Urol; 2016 Feb; 69(2):352-60. PubMed ID: 26382085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
    Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
    Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.
    Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA
    Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma.
    Morgan TM; Tang D; Stratton KL; Barocas DA; Anderson CB; Gregg JR; Chang SS; Cookson MS; Herrell SD; Smith JA; Clark PE
    Eur Urol; 2011 Jun; 59(6):923-8. PubMed ID: 21295907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.
    Peyton CC; Abel EJ; Chipollini J; Boulware DC; Azizi M; Karam JA; Margulis V; Master VA; Matin SF; Raman JD; Sexton WJ; Wood CG; Spiess PE
    Eur Urol Focus; 2020 Jan; 6(1):104-111. PubMed ID: 30206003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma.
    Roussel E; Campi R; Larcher A; Verbiest A; Antonelli A; Palumbo C; Derweesh I; Ghali F; Bradshaw A; Meagher MF; Heck M; Amiel T; Kriegmair MC; Rubio J; Musquera M; D'Anna M; Autorino R; Guruli G; Veccia A; Linares-Espinos E; Van Bruwaene S; Hevia V; Porpiglia F; Checcucci E; Minervini A; Mari A; Pavan N; Claps F; Marchioni M; Capitanio U; Beuselinck B; Mir MC; Albersen M;
    Eur Urol Oncol; 2020 Aug; 3(4):523-529. PubMed ID: 32414697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
    Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
    Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
    Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
    Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Nomogram to Predict Significant Estimated Glomerular Filtration Rate Reduction After Robotic Partial Nephrectomy.
    Martini A; Cumarasamy S; Beksac AT; Abaza R; Eun DD; Bhandari A; Hemal AK; Porter JR; Badani KK
    Eur Urol; 2018 Dec; 74(6):833-839. PubMed ID: 30224195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
    Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
    Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.